Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment
Mantle cell lymphoma (MCL) encompasses nearly 6% of all the non-Hodgkin lymphomas. It is considered an incurable neoplastic process arising from B cells. The cytogenetic abnormality t(11;14) (q13; q32) leading to cyclin D1 overexpression is the sentinel genetic event and provides an exceptional marker for diagnosis. MCL is generally considered to have an aggressive course as compared with other indolent lymphomas with traditionally reported median survival of 3–5 years. According to the 2016 WHO classification, there are two major known variants of MCL: classical which affects the lymph nodes and extra nodal sites and leukemic non-nodal MCL (L-NN-MCL) which characteristically involves the bone marrow, peripheral blood, and the spleen. It is important to distinguish between classical and leukemic non-nodal MCL since the latter variant of MCL follows a rather indolent course with a wait and watch approach in order to avoid overtreatment. However, a subset of patients with L-NN-MCL can transform into a more aggressive course requiring treatment. Current evidence suggests those patients with alteration in TP53 gene do not respond to standard chemotherapy agents and may need targeted therapy. In this review, we describe the characteristics of L-NN-MCL, its diagnosis, and management.
KeywordsLeukemic Mantle cell lymphoma Non-nodal P53 gene mutation Diagnosis Treatment
Compliance with Ethical Standards
Conflict of Interest
Akriti Gupta Jain, Chung-Che Chang, Sarfraz Ahmad, and Shahram Mori declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 14.• Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895–8 This paper describes that in non-nodal type of MCL, the presence of specific genetic anomalies identified disease progression risk. The presence of 17p/TP53 alterations was consistent with more aggressive disease.CrossRefGoogle Scholar
- 17.• Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121–7 This paper emphasizes that mantle cell lymphoma can present with disease limited to blood and the bone marrow, and the recognition of this variant could help treatment decision and possibly avoid unnecessary treatment.CrossRefGoogle Scholar
- 18.Campo E, Jares P. Mantle cell lymphoma. In: Jaffe ES, Arber DA, Quintanilla-Martinez L, Campo E, Harris NL, editors. Hematopathology, vol. 2, Chapter 22. Amsterdam: Elsevier; 2016. p. 397–414.e7.Google Scholar
- 29.••Chapman-Fredricks J, Sandoval-Sus J, Vega F, Lossos IS. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14. Ann Diagn Pathol. 2014;18(4):214–9 In this study, the authors identified three cases of leukemic, non-nodal-MCL in which TP53, ATM, and/or 13q14 deletions were identified and had an aggressive disease course.CrossRefGoogle Scholar
- 30.•• Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604–11 This study demostrates that high-dose cytarabine was ineffective in MCL patients with deletions of CDKN2A (p16) or TP53, and thus should be candidates for alternative therapeutic strategies.CrossRefGoogle Scholar
- 31.•• Eskelund CW, Dahl C, Hansen JW, et al. Mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–10 This paper reports that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to the standard chemotherapies and autologous stem-cell transplantation.CrossRefGoogle Scholar
- 33.•• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16 This study established the BTK inhibitor ibrutinib as a highly active agent showing durable single-agent activity in the relapsed and refractory mantle-cell lymphoma.CrossRefGoogle Scholar
- 36.Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood. 2005;105(7):2677–84.CrossRefGoogle Scholar
- 38.Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, et al. Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry. Clin Cancer Res. 2014;20(4):1007–19.CrossRefGoogle Scholar